NCT02298387View on ClinicalTrials.gov

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 22, 2014

Primary Completion Date

May 23, 2017

Study Completion Date

September 8, 2017

Conditions
Advanced Solid Tumor Malignancies
Interventions
DRUG

OMP-305B83

intravenous (in the vein) infusions

Trial Locations (4)

48109

University of Michigan Health System, Ann Arbor

73104

University of Oklahoma Stephenson Cancer Center, Oklahoma City

80045

University of Colorado Anschutz Medical Campus, Aurora

85258

Oncology Research Associates, PLLC d/b/a Pinnacle Oncology Hematology, Scottsdale

Sponsors
All Listed Sponsors
lead

OncoMed Pharmaceuticals, Inc.

INDUSTRY